Nasdaq

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined ...

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and ...
Reuters

Mustang Bio Receives Advanced Therapy Medicinal Product Classification For Mb-107 Lentiviral Gene Therapy

* MUSTANG BIO RECEIVES ADVANCED THERAPY MEDICINAL PRODUCT CLASSIFICATION FROM EUROPEAN MEDICINES AGENCY FOR MB-107 LENTIVIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNODEFICIENCY Source text for ...
CBS

4. Changing and adding codes to the NACE classification

The findings presented in this section are based on desk research and interviews with NACE experts working at organisations such as Statistics Netherlands and the European Joint Research Centre. 4.1 ...
BioWorld

Myriad study shows discrepancies in Clinvar database for hereditary cancer classification

Public genetic databases could have a discrepancy in identifying BRCA1 and BRCA2 variant classifications, which can introduce uncertainty and diminish patient care, according to a study by Myriad ...
CBS

1. Introduction

The environmental problems caused by adverse effects of plastics and other materials has increased interest for bio-based materials. In this context, projects such as the EU funded BioMonitor set out ...
Reuters

Atara Bio receives ATMP classification for its EBV-CTLs product candidate from EMA

* Atara Bio receives advanced therapy medicinal product classification for allogeneic epstein-barr virus specific cytotoxic T-Lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) Source text ...